Abstract

10020 Background: Ependymoma is the third most common pediatric brain tumor. Despite the importance of surgical resection and pathology, its clinical course is highly unpredictable and the biological behavior is largely unknown. As part of ongoing studies to identify potential biological and therapeutic markers for the disease, we analyzed the role of telomere maintenance, which is required for cancers to sustain growth and evade senescence. Methods: We analyzed 111 primary and recurrent ependymomas that were resected at the Hospital for Sick Children in Toronto between 1986 and 2004. A tissue array was constructed. hTERT and γH2AX expression were evaluated. Thirty-one frozen samples were additionally analyzed for telomere length (TRF) and telomerase activity (TRAP assay). Results: Of the 111 samples, 40 tumors were hTERT(-) with progression-free survival (PFS) of 83±15% and 71 were hTERT(+) with PFS of 21±9% (p<0.0001). Of the 65 patients with primary ependymomas, five-yr overall survival (OS) were 84±7% and 41±7% for hTERT(-) and hTERT(+) tumors, respectively (p=0.001). There was good correlation between telomerase activity and hTERT expression (κ=0.637). Multivariate analysis revealed hTERT expression to be the single most important predictor of survival of all known pathological, clinical and treatment factors (HR 60.4 (CI 6.4–561)). TRF measurement revealed lack of alternative lengthening of telomeres (ALT) and heterogenous telomere length in pediatric ependymomas. We observed a trend for better prognosis with telomere dysfunction manifested by shorter telomeres and positive γH2AX. Conclusions: This study suggest that telomere maintenance represents the first known biologic prognostic factor for intracranial ependymomas. Telomerase activity highlights the importance of senescence in carcinogenesis and a possible target for novel treatment approaches for the disease. No significant financial relationships to disclose.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call